Merck KGaA (OTCMKTS:MKGAF) Shares Up 5.2% – Still a Buy?

Merck KGaA (OTCMKTS:MKGAF) shares were up 5.2% on Wednesday . The stock traded as high as $158.1360 and last traded at $157.7760. 93 shares were traded during trading, a decline of 85% from the average session volume of 604 shares. The stock had previously closed at $149.9670.

Merck KGaA Price Performance

The business’s 50-day simple moving average is $161.07 and its 200-day simple moving average is $149.78. The stock has a market cap of $19.49 billion, a PE ratio of 23.03 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On Merck KGaA

Hedge funds have recently made changes to their positions in the business. Puzo Michael J bought a new stake in Merck KGaA in the second quarter valued at $2,230,000. Ames National Corp bought a new position in Merck KGaA in the 2nd quarter worth $1,009,000. Notis McConarty Edward bought a new position in Merck KGaA in the 2nd quarter worth $1,304,000. MASTERINVEST Kapitalanlage GmbH purchased a new stake in shares of Merck KGaA in the 2nd quarter worth about $4,896,000. Finally, Somerville Kurt F purchased a new stake in shares of Merck KGaA in the 2nd quarter worth about $1,997,000. 0.10% of the stock is owned by hedge funds and other institutional investors.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.